drugset / Trial / NCT04389931

Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement

NCT04389931

Completed 18 enrolled Universidad Nacional Andres Bello
RandomizedParallel-groupTriple-blindTreatment

Summary

This study evaluates the effect of the systemic administration of Omega 3 as a therapy associated with non-surgical periodontal treatment, in the clinical and microbiological variables of patients with Moderate Periodontitis with moderate rate of progression (Stage II grade B) and Severe Periodontitis with potential for additional tooth loss and moderate rate of progression (Stage III grade B). A double-blind, randomized, controlled trial was conducted with 18 voluntary patients with a history of moderate to severe chronic periodontitis, who met the inclusion and exclusion criteria and signed an informed consent. The intervention group received Scaling and Root Planning (SRP) plus Omega 3, and the control group received SRP plus placebo. Probing depth (PD), Clinical Attachment Level (CAL), Biofilm Index (BI) and Bleeding on Probing (BOP) were evaluated as clinical variables while Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), Treponema denticola (Td), Fusobacterium nucleatum (Fn) were the microbiological variables detected by conventional Polymerase chain reaction (PCR).

Timeline

Start
2016-03
Primary completion
2016-09
Completion
2016-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3 fatty acids Unknown 1 g Oral

Indications